Avidity Biosciences Inc (NASDAQ:RNA) has a beta value of 0.92 and has seen 1.67 million shares traded in the recent trading session. The company, currently valued at $4.03B, closed the recent trade at $33.47 per share which meant it gained $2.02 on the day or 6.42% during that session. The RNA stock price is -67.31% off its 52-week high price of $56.00 and 35.73% above the 52-week low of $21.51. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.98 million shares traded. The 3-month trading volume is 1.48 million shares.
The consensus among analysts is that Avidity Biosciences Inc (RNA) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Sporting 6.42% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RNA stock price touched $33.47 or saw a rise of 4.21%. Year-to-date, Avidity Biosciences Inc shares have moved -21.30%, while the 5-day performance has seen it change 16.22%. Over the past 30 days, the shares of Avidity Biosciences Inc (NASDAQ:RNA) have changed 4.56%. Short interest in the company has seen 16.34 million shares shorted with days to cover at 11.56.
Wall Street analysts have a consensus price target for the stock at $70, which means that the shares’ value could jump 52.19% from the levels at last check today.. The projected low price target is $70.0 while the price target rests at a high of $70.0. In that case, then, we find that the latest price level in today’s session is -109.14% off the targeted high while a plunge would see the stock gain -109.14% from the levels at last check today..
Avidity Biosciences Inc (RNA) estimates and forecasts
The company’s shares have gained 11.83% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -34.37% over the past 5 years. Earnings growth for 2025 is a modest -36.47% while over the next 5 years, the company’s earnings are expected to decrease by -5.13%.
RNA Dividends
Avidity Biosciences Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders own 5.17% of the company shares, while shares held by institutions stand at 112.41% with a share float percentage of 118.54%. Investors are also buoyed by the number of investors in a company, with Avidity Biosciences Inc having a total of 320.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 16.16 million shares worth more than $660.1 million. As of 2024-06-30, FMR LLC held 15.1121% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 10.92 million shares as of 2024-06-30. The firm’s total holdings are worth over $445.94 million and represent 10.2093% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund . As of Mar 31, 2025 , the former fund manager holds about 3.68% shares in the company for having 4.43 shares of worth $150.61 million while later fund manager owns 3.74 shares of worth $127.0 million as of May 31, 2025 , which makes it owner of about 3.10% of company’s outstanding stock.
